251 related articles for article (PubMed ID: 34663639)
21. Leptin as a mediator of tumor-stromal interactions promotes breast cancer stem cell activity.
Giordano C; Chemi F; Panza S; Barone I; Bonofiglio D; Lanzino M; Cordella A; Campana A; Hashim A; Rizza P; Leggio A; Győrffy B; Simões BM; Clarke RB; Weisz A; Catalano S; Andò S
Oncotarget; 2016 Jan; 7(2):1262-75. PubMed ID: 26556856
[TBL] [Abstract][Full Text] [Related]
22. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
Doherty MR; Parvani JG; Tamagno I; Junk DJ; Bryson BL; Cheon HJ; Stark GR; Jackson MW
Breast Cancer Res; 2019 Apr; 21(1):54. PubMed ID: 31036052
[TBL] [Abstract][Full Text] [Related]
23. Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells.
Wang D; Xiang T; Zhao Z; Lin K; Yin P; Jiang L; Liang Z; Zhu B
Oncotarget; 2016 Nov; 7(46):76006-76020. PubMed ID: 27738346
[TBL] [Abstract][Full Text] [Related]
24. Human Primary Breast Cancer Stem Cells Are Characterized by Epithelial-Mesenchymal Plasticity.
Strietz J; Stepputtis SS; Follo M; Bronsert P; Stickeler E; Maurer J
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670400
[TBL] [Abstract][Full Text] [Related]
25. A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties.
Liu S; Sun Y; Hou Y; Yang L; Wan X; Qin Y; Liu Y; Wang R; Zhu P; Teng Y; Liu M
J Hematol Oncol; 2021 Oct; 14(1):178. PubMed ID: 34715882
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia-induced circSTT3A enhances serine synthesis and promotes H3K4me3 modification to facilitate breast cancer stem cell formation.
Xu M; Liu X; Zhou X; Qin Y; Yang L; Wen S; Qiu Y; Chen S; Tang R; Guo Y; Liu M; Sun Y
Pharmacol Res; 2023 Nov; 197():106964. PubMed ID: 37865128
[TBL] [Abstract][Full Text] [Related]
27. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
28. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
[TBL] [Abstract][Full Text] [Related]
29. The Role of Breast Cancer Stem Cells and Some Related Molecular Biomarkers in Metastatic and Nonmetastatic Breast Cancer.
El Abbass KA; Abdellateif MS; Gawish AM; Zekri AN; Malash I; Bahnassy AA
Clin Breast Cancer; 2020 Aug; 20(4):e373-e384. PubMed ID: 32299754
[TBL] [Abstract][Full Text] [Related]
30. O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells.
Cheng JY; Hung JT; Lin J; Lo FY; Huang JR; Chiou SP; Wang YH; Lin RJ; Wu JC; Yu J; Yu AL
Front Immunol; 2021; 12():791551. PubMed ID: 35046949
[TBL] [Abstract][Full Text] [Related]
31. A novel Lnc408 maintains breast cancer stem cell stemness by recruiting SP3 to suppress CBY1 transcription and increasing nuclear β-catenin levels.
Wen S; Qin Y; Wang R; Yang L; Zeng H; Zhu P; Li Q; Qiu Y; Chen S; Liu Y; Hou Y; Tang X; Liu M; Tu G
Cell Death Dis; 2021 May; 12(5):437. PubMed ID: 33934099
[TBL] [Abstract][Full Text] [Related]
32. Targeting specificity of dendritic cells on breast cancer stem cells: in vitro and in vivo evaluations.
Nguyen ST; Nguyen HL; Pham VQ; Nguyen GT; Tran CD; Phan NK; Pham PV
Onco Targets Ther; 2015; 8():323-34. PubMed ID: 25674007
[TBL] [Abstract][Full Text] [Related]
33. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
[TBL] [Abstract][Full Text] [Related]
34. MiR-7 reduces the BCSC subset by inhibiting XIST to modulate the miR-92b/Slug/ESA axis and inhibit tumor growth.
Li M; Pan M; You C; Zhao F; Wu D; Guo M; Xu H; Shi F; Zheng D; Dou J
Breast Cancer Res; 2020 Mar; 22(1):26. PubMed ID: 32143670
[TBL] [Abstract][Full Text] [Related]
35. Targeting highly expressed extracellular HSP90 in breast cancer stem cells inhibits tumor growth in vitro and in vivo.
Stivarou T; Stellas D; Vartzi G; Thomaidou D; Patsavoudi E
Cancer Biol Ther; 2016 Aug; 17(8):799-812. PubMed ID: 27259689
[TBL] [Abstract][Full Text] [Related]
36. IL23 induces IL23R recycling and amplifies innate receptor-induced signalling and cytokines in human macrophages, and the IBD-protective IL23R R381Q variant modulates these outcomes.
Sun R; Hedl M; Abraham C
Gut; 2020 Feb; 69(2):264-273. PubMed ID: 31097538
[TBL] [Abstract][Full Text] [Related]
37. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications.
Zeng X; Liu C; Yao J; Wan H; Wan G; Li Y; Chen N
Pharmacol Res; 2021 Jan; 163():105320. PubMed ID: 33271295
[TBL] [Abstract][Full Text] [Related]
39. Caffeic Acid Phenethyl Ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells.
Omene CO; Wu J; Frenkel K
Invest New Drugs; 2012 Aug; 30(4):1279-88. PubMed ID: 21537887
[TBL] [Abstract][Full Text] [Related]
40. Leptin receptor maintains cancer stem-like properties in triple negative breast cancer cells.
Zheng Q; Banaszak L; Fracci S; Basali D; Dunlap SM; Hursting SD; Rich JN; Hjlemeland AB; Vasanji A; Berger NA; Lathia JD; Reizes O
Endocr Relat Cancer; 2013 Dec; 20(6):797-808. PubMed ID: 24025407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]